CStone Pharmaceuticals, a Chinese clinical-stage biopharmaceutical company, has raised about HK$2.23 billion (US$284.09 million) in an initial public offering on the Hong Kong stock exchange on Tuesday, which makes it become the sixth pre-profit Chinese biotech company to float shares in the financial hub.
GIC-Backed Chinese Biopharma Firm CStone Raises $284M In HK IPO comes originally from China Money Network. All Rights Reserved.